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Abstract 
Introduction: We evaluated the presence of Porphyromonas gingivalis (Pg) DNA in the 
synovial tissue through synovial biopsy and in other compartments of RA patients in 
comparison with patients affected by other arthritides. Possible links with clinical, 
immunologic and genetic features were assessed. 
Methods: Peripheral blood (PB), sub-gingival dental plaque, synovial fluid (SF) and synovial 
tissue samples were collected from 69 patients with active knee arthritis (32 with RA and 37 
with other arthritides, of which 14 with undifferentiated peripheral inflammatory arthritis - 
UPIA). Demographic, clinical, laboratory and immunological data were recorded. The 
presence of Pg DNA was evaluated through PCR. The HLA-DR haplotype was assessed for 
45 patients with RA and UPIA.  
Results: No differences arose in the positivity for Pg DNA in the sub-gingival plaque, PB 
and SF samples between RA and the cohort of other arthritides. Full PB samples showed a 
higher positivity for Pg DNA than plasma samples (11.8% vs. 1.5%, p=0.04). Patients with 
RA showed a higher positivity for Pg DNA in the synovial tissue compared to controls 
(33.3% vs. 5.9%, p<0.01). UPIA and RA patients carrying the HLA DRB1*04 allele showed 
a higher positivity for Pg DNA in the synovial tissue compared to patients negative for the 
allele (57.1% vs. 16.7%, p=0.04). RA patients positive for Pg DNA in the sub-gingival 
plaque had a lower disease duration and a higher peripheral blood leucocytes and neutrophils 
count. The presence of Pg DNA did not influence disease activity, disease disability or 
positivity for autoantibodies.  
Conclusions: The presence of Pg DNA in the synovial tissue of RA patients suggests a 
pathogenic role of the bacterium. The higher positivity of Pg DNA in full peripheral blood 
and synovial tissue samples compared to plasma and synovial fluid suggests a possible 
intracellular localization of Pg, in particular in patients positive for HLA-DR4. 
Introduction 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease. Reasons 
for the loss of immunologic tolerance against auto-antigens are partially unknown. Genetic 
factors are thought to be responsible only for 50-60% of the RA heritability [1]. HLA alleles 
DRB1*01 and *04, the main genetic risk factor for RA, are primarily involved in the antigen 
presentation process [2]. Environmental factors like smoking, together with genetic factors, 
play roles in the development of RA, possibly through the loss of tolerance against 
citrullinated peptides [3]. Citrullination is a process involved in the pathogenesis of RA, and 
the conversion of arginine to citrulline allows for a high affinity antigen interaction with the 
HLA-DRB1*04 allele [4]. Bacteria may play a role as well, activating the immune system 
against auto-antigens, through the mechanism of the so-called “molecular mimicry” [5]. 
Following the model of reactive arthritis [6], the research of bacterial antigens in the joint 
compartment of RA patients lent to few positive results, mainly in the synovial tissue 
compared to the synovial fluid [7], thus supporting the idea of a prevalence of intracellular 
bacteria. Alive bacteria have never been isolated, to date, in the joint compartment of RA 
patients. The role of these bacterial structures is unknown: they can be bystanders related to 
the recruitment of inflammatory cells, or they may play a specific part in the etiology of the 
disease. 
Recently, Porphyromonas gingivalis (Pg), a periodontal anaerobic intracellular 
pathogen [8], has been associated to RA and the pathogenesis of the disease [9, 10], mainly 
for the ability of the bacterium to citrullinate host and bacterial peptides [11], unique in the 
prokaryotic world. Periodontitis is known to be epidemiologically associated to RA [12], and 
its pathogenesis, including the genetic background, has many points in common with RA 
[13]. As a support for the possible role of Pg in the pathogenesis of RA, antibodies against Pg 
have been found to be associated with RA and with anti-citrullinated protein antibodies 
(ACPA) [14]. Moreover, the DNA of Pg has been detected in the synovial fluid and plasma 
samples from patients with RA [15], and the coexistence of RA and periodontitis increased 
the probability of finding Pg DNA in these compartments [16]. Several studies on animal 
models seem to strengthen the idea of a relationship between Pg and the pathogenesis of RA 
[17, 18, 19, 20], although possible biases should be taken into account. 
To date, given the mainly intracellular life of Pg, there are no data regarding the 
presence of the bacterium in the synovial tissue of RA patients, nor concerning the possible 
link with clinical and genetic factors. The aims of the study were a) to see whether Pg DNA 
could be found in the synovial tissue of RA patients and compare it to patients affected by 
other arthritides, b) to determine whether the prevalence of DNA positivity in other 
compartments such as dental plaque and peripheral blood of RA patients could differ from 
that of patients with other arthritides, and c) to assess the possible links between the presence 
of Pg DNA and clinical, immunological and genetic features. 
 
Methods 
Patients: case-control study 
Sixty-nine consecutive patients with active knee arthritis undergoing synovial biopsy from 
October 2010 till February 2012 at the Division of Rheumatology of the Catholic University 
of the Sacred Heart of Rome have been included in the study. Twenty-six healthy donors 
were included in the study, as well. The ethical approval for the study was obtained from the 
Catholic University of the Sacred Heart Ethical Committee. Informed written consent was 
obtained from all the patients and healthy donors. The research is in compliance with the 
Helsinki Declaration. The following samples were collected for every patient: a) peripheral 
blood, b) sub-gingival dental plaque as previously described [16], c) synovial fluid through 
joint aspiration, d) synovial tissue through ultrasound-guided percutaneous needle synovial 
biopsy (14G Tru-cut Precisa 1410 - Hospital Service). Thirty-two (46.4%) rheumatoid 
arthritis (RA) patients fulfilling at least six of the ACR/EULAR criteria for RA [21] were 
considered as case population. The control group consisted of 37 subjects with other 
arthritides. Moreover, samples of peripheral blood and sub-gingival dental plaque were 
collected from healthy donors. 
Laboratory and clinical data 
All patients’ sera were tested for the presence of ACPA (Axis-Shield Diagnostics, Dundee, 
UK), IgM and IgA-rheumatoid factor (RF) autoantibodies (Orgentec diagnostika, Mainz, 
Germany for IgM and IgA RFs). IgM and IgA RF were considered positive if values were ≥ 
20 U/ml; ACPA were positive if ≥ 5 U/ml. Patients were tested for erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP), complete blood count and synovial fluid cell count, as 
well. Tender and swollen joint count and Ritchie articular index were obtained, as well as 
pain visual analogue scale, global health status and health assessment questionnaire disability 
index (HAQ-DI). Disease activity score (DAS) was calculated in order to assess the disease 
activity of patients with rheumatoid arthritis. The presence of joint erosions was evaluated 
through conventional hands and feet radiograms. Other clinical variables (e.g. smoking) were 
obtained through medical history investigation. Actual therapies with conventional and/or 
biologic disease modifying anti-rheumatic drugs (DMARDs) and/or steroid were recorded. 
Human leukocyte antigen-DR (HLA-DR) assessment 
DNA was extracted by a blood sample through QuickGene DNA Whole Blood kit (Life 
Science, Fujifilm Corporation, Tokyo, Japan). The extracted DNA was used for molecular 
typing of the HLA-DR haplotype at allele group level, using the Inno-LiPA HLA-DRB1 
Amp Plus kit (Innogenetics N.V., 9052 Gent, Belgium), according to manufacturer’s 
instructions. 
Histological analysis of the synovial tissue 
Histological examination of the synovial tissue samples through direct optical microscopy 
was performed on 43 of the studied patients (62.3%). The other samples were excluded due 
to the lack of informativeness. Tissue specimens were fixed with formaldehyde, dehydrated 
with alcohol, diaphanised with xylol, included in paraffin, sectioned in slices of ~10 µm, 
applied on a slide and then coloured with haematoxylin-eosin. A Leica DM 2000 optical 
microscope has been used for the analysis (Leica Microsystems GmbH, Wetzlar, Germany). 
Bioptic samples were evaluated by two independent assessors. A binary score was used in 
order to classify the infiltrate patterns as aggregate or diffuse [22].  
Porphyromonas gingivalis DNA detection 
Nucleic acid isolation were performed after resuspension of sub-gingival dental plaque 
samples and shredding of the synovial tissue specimens; all the samples were incubated for 
30’ at 37°C with a lysis solution and lysozyme (5 mg/ml), and then for 15’ at 56°C with the 
addition of proteinase K. DNA was extracted using a QIAmpDNA Minikit (Qiagen SpA, 
Milan, Italy) according to the manufacturer’s instructions. The presence of Pg DNA was 
tested through polymerase chain reaction (PCR). Briefly, oligonucleotides 5’-AGG CAG 
CTT GCC ATA CTG CG-3’ and 5’-ACT GTT AGC AAC TAC CGA TGT-3’ were used as 
primers for a 404 bp amplicon derived from the 16S rRNA, as previously described [23]. 
Each assay used 5 µl of eluted nucleic acids and 20 pmol of each primer. The reaction 
mixture contained 25 µl of HotStart Taq Master Mix (Qiagen S.p.A., Milan, Italy) and 10 µl 
of RNase-free water in a final volume of 50 µl. The amplification profile consisted of 15 min 
at 95°C to activate the HotStar-Taq DNA polymerase (Qiagen S.p.A., Milan, Italy) followed 
by 40 cycles at 95°C for 30 sec, 60°C for 45 sec and 72°C for 45 sec. Assays were performed 
with an iCycler Thermal cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Amplicons 
were detected by electrophoresis in a 2% agarose gel, visualized by ethidium bromide 
staining. In each amplification run, distilled water was used as negative control and genomic 
DNA from ATCC 33277 strain as positive control. Procedures to prevent specimen 
contamination and PCR carryover were rigorously observed at all stages. To assess 
sensitivity, specific PCR products were cloned into the pCR2.1 vector (Invitrogen, San 
Diego, CA, USA) and quantified by O.D. measurement. Constructs were serially diluted and 
subsequently amplified with Pg-specific primers. PCR for P. gingivalis was shown to detect 
concentrations as low as 5 copies per sample. Randomly selected samples were retested for 
the presence of P. gingivalis DNA using real-time PCR Standard kit (Genesig, Eppendorf, 
England) according to manufacturer’s directions. 
Statistical analysis 
Data were analyzed using IBM SPSS Statistics 20.0 (IBM Corp., Armonk, NY, USA) and 
Prism software 5.0 (Graph-Pad, S. Diego, CA 92121-USA).  
Categorical and quantitative variables were respectively described as numbers, 
percentages (%) and mean ± standard deviation (SD). Mann-Whitney’s test was used to 
compare continuous variable. Categorical variables were analyzed using χ2 test or Fisher’s 
test, depending on sample size restrictions.  
The concordance among the PCR and real-time PCR tests results was evaluated by Cohen’s 
kappa statistic, as described by Fleiss [24].  
A value of p < 0.05 was considered statistically significant. 
 
Results 
Patients’ clinical and immunological characteristics 
Demographic and clinical data of the 32 patients with RA, 14 with undifferentiated peripheral 
inflammatory arthritis (UPIA) and 23 with other arthritides included in this study are 
summarized in Table 1. Four RA patients retired the consent for DNA analysis after having 
obtained the informed consent.  
Cases and controls were comparable for age, sex and smoking status. 9 of the RA 
patients (28.1%) had an early disease (ERA) with a disease duration lower than 1 year. The 
patients with other arthritides comprised 12 patients with seronegative spondyloarthropaties 
(SpA) and 11 patients with other forms of arthritis (i.e. gout, polymyalgia rheumatica, 
Sjögren syndrome, systemic lupus erythematosus, eosinophilic fasciitis, adult-onset Still’s 
disease, osteoarthritis).  
RA patients had a high disease activity and a high disability at the moment of the 
biopsy (mean DAS 3.74 ± 1.17, mean HAQ-DI 1.40 ± 0.78). Disease activity and disability 
were higher in RA patients than in patients affected by UPIA (p < 0.01). 15 (48.4%) RA 
patients and 3 (25.0%) UPIA patients were positive for at least one tested autoantibody 
(ACPA, IgM and IgA RF). The presence of joint erosions was significantly higher in RA 
patients compared to UPIA (63.3% vs. 25.0%, p = 0.01) and to patients affected by other 
arthritides (22.7%, p < 0.01 vs. RA patients). ERA patients had a lower prevalence of 
erosions compared to patients with a long-standing disease (LSRA) (22.2% vs. 81.0%, p < 
0.01). Groups were comparable for DMARDs and steroid therapy, although RA patients were 
more frequently receiving biologic therapy (RA vs. other arthritides: p < 0.01) (Table 1). 
Porphyromonas gingivalis DNA detection 
The analysis of the healthy donors showed a positivity for Pg DNA in the sub-gingival dental 
plaque in 7 subjects (26.9%). No positivity arose in the peripheral blood of healthy subjects.  
Positive results for Pg DNA in the patients’ population are summarized in Table 2 and 
Additional file 1, Table S1. When considering the global positivity for Pg DNA in all the 
compartments analyzed, no differences arose among cases and controls.  
When considering the single areas analyzed, 59.3% of all the patients studied were 
positive for Pg DNA in the sub-gingival plaque, 20.9% were positive in the joint 
compartment, and only one patient (affected by LSRA) was positive in the plasma sample. 
No significant differences arose among patients and healthy donors.  
Pg DNA was more present in whole peripheral blood samples than in plasma samples 
(11.8% vs. 1.5%, p = 0.04). 
When considering possible differences among cases and controls, no distinction arose 
in the positivity for Pg DNA in the sub-gingival plaque, plasma and synovial fluid samples. 
(Table 2). Nevertheless, when analyzing the synovial tissue, the positivity for Pg DNA was 
significantly different among the subjects analyzed (χ2 = 8.05, p = 0.02). In particular, 
patients with RA showed a higher positivity of Pg DNA in the synovial tissue compared to 
controls (33.3% in RA vs. 5.9% in UPIA + Others, p < 0.01) and also when compared to 
UPIA (0%, p = 0.04 vs. RA patients) or other arthritides (8.7%, p < 0.01 vs. RA patients), 
whereas the difference was not significant when comparing RA only to SpA patients (16.7% 
in SpA, p = ns vs. RA patients). No differences arose among LSRA and ERA patients (p = 
ns), though patients with UPIA and ERA showed a trend for a higher positivity for Pg DNA 
in the sub-gingival plaque than patients with LSRA (75% vs. 47.4%, p = 0.1).  
These results were replicated using the real-time PCR Standard kit. The concordance 
between the PCR and the real-time PCR tests results was good (84.8%, Kappa = 0.67, p < 
0.001, 95% CI 0.54 - 0.80).  
Pg DNA positivity and HLA 
Forty-five of the 46 patients with RA and/or UPIA were genotyped for HLA DR. DNA 
extraction and typing of one patient with UPIA was unsuccessful after 2 attempts. 20 patients 
(44.4%) were positive for HLA DRB1*01 and/or DRB1*04 (shared epitope - SE). 13 patients 
(28.9%) were positive for HLA DRB1*01 and 9 (20%) for HLA DRB1*04.  
When evaluating a possible association between a specific HLA genotype and the 
positivity for Pg DNA, no relationship arose among HLA-SE and Pg detection in any of the 
compartments analyzed. However, when considering the single alleles (DRB1*01 or 
DRB1*04), UPIA and RA patients carrying HLA DRB1*04 allele showed a higher positivity 
for Pg DNA in the synovial tissue compared to patients negative for the allele (57.1% vs. 
16.7%, p = 0.04). The association between the presence of HLA DRB1*04 and the positivity 
for Pg DNA was confirmed also when considering the whole articular compartment (synovial 
fluid and synovial tissue) (joint Pg positivity: 55.6% in HLA DRB1*04 positive patients vs. 
17.6% in HLA DRB1*04 negative patients, p = 0.03). The same trend occurred when 
considering only patients affected by RA (joint Pg DNA positivity: 55.6% in HLA DRB1*04 
positive patients vs. 21.7% in HLA DRB1*04 negative ones) (Additional file 2, Figure S1).  
When considering a possible association between clinical variables, HLA and Pg 
positivity, UPIA and RA patients who were smokers and/or positive for ACPA 
autoantibodies and/or positive for HLA DRB1*04 allele were more frequently positive for Pg 
DNA in the synovial tissue, compared to patients who were negative for all these 
clinical/genetic variables (42.9% vs. 10.5%, p = 0.05) (Additional file 3, Table S2). 
Pg DNA positivity and autoantibodies 
When evaluating patients affected by RA, no significant relationship arose between the 
presence of Pg DNA and the positivity for the tested autoantibodies (ACPA, IgM and IgA 
RF). However, RA patients positive for Pg DNA in the synovial fluid showed a trend for a 
higher positivity for IgM RF, compared to patients negative for Pg DNA (100% vs. 25.0%, p 
= 0.08). No relationship arose between the positivity for Pg DNA in any of the compartments 
analyzed and the title of autoantibodies in seropositive RA patients. 
Pg DNA positivity and clinical characteristics 
When analyzing the possible links between Pg DNA and the clinical variables in patients 
affected by RA, we found that patients positive for Pg DNA in the sub-gingival plaque had a 
shorter disease duration (Pg positive 4.2 ± 5.9 years vs. Pg negative 9.3 ± 8.4 years, p = 0.03), 
and tended to be more commonly smokers compared to patients negative for Pg in the plaque 
sample (Pg positivity: smokers 88.9% vs. non-smokers 54.5%, p = 0.07). No differences 
arose regarding the other clinical variables analyzed. In particular, no differences were noted 
in the activity and disability indexes (DAS and HAQ-DI) among RA patients positive or 
negative for Pg DNA.  
The presence of Pg DNA in the sub-gingival plaque was associated with 
modifications in the cell blood count: RA patient positive for Pg DNA had a higher 
leucocytes and neutrophils count compared to patients negative for the bacterium (leucocytes: 
Pg positive RA 8.04 ± 1.82 cells x 109/L vs. Pg negative RA 6.41 ± 1.05 cells x 109/L, p = 
0.02; Neutrophils: Pg positive RA 5.23 ± 1.69 cells x 109/L vs. Pg negative RA 3.76 ± 1.09 
cells x 109/L, p = 0.03) (Figure 1).  
No relationship arose between Pg DNA positivity and synovial fluid cell count.  
Pg DNA and the histological pattern of the synovial tissue 
13 patients (30.2%) presented an aggregate organization of the synovial tissue, whereas the 
other 30 (69.8%) had a diffuse infiltrate. An aggregate pattern was more frequent among RA 
patients (aggregate in RA: 76.9% vs. aggregate in other patients: 23.1%, p = 0.04) and was 
associated with the positivity for ACPA (ACPA positivity: aggregate 61.5% vs. diffuse 
14.3%, p = 0.004), for IgM RF (IgM RF positivity: aggregate 46.2% vs. diffuse 10.7%, p = 
0.02) and for IgA RF (IgA RF positivity: aggregate 30.8% vs. diffuse 3.6%, p = 0.02). 
Patients with an aggregate pattern presented a higher neutrophils count in the synovial fluid 
(SF) than patients with a diffuse infiltrate (SF neutrophils: aggregate 19.75 ± 15.18 cells x 
109/l vs. 8.06 ± 9.72 cells x 109/l, p = 0.01). An aggregate pattern of the synovial tissue was 
more frequent among people carriers of HLA shared epitope compared to patients negative 
for the alleles (50.0% vs. 9.1%, p = 0.04). 
When evaluating a possible link between a specific structural pattern of the synovial 
tissue and the positivity for Porphyromonas gingivalis DNA, no relationship arose in any of 
the compartments analysed. 
 
Discussion 
In the scientific community it is well accepted that Porphyromonas gingivalis (Pg) latent-
chronic infection might be one determinant of the citrullination process, because of the 
peptidyl-arginine-deiminase activity that could potentially lead to the loss of tolerance to 
citrullinated peptides, thus leading to the occurrence of anti-citrullinated peptides 
autoantibodies (ACPA) [11, 13]. Previously it was shown that antibodies against Pg were 
more frequent in RA (and in periodontitis patients) than in controls [25] and that these 
antibodies correlated with ACPA. Since a correlation with CRP was also observed the main 
conclusion was that this organism could play a role in disease risk and progression of RA. 
The occurrence of periodontal disease in many patients with RA is also well established and 
there is evidence that Pg bacteria induce inflammatory cytokines and proteases by either 
mononuclear cells and fibroblasts [26, 27]. Therefore Pg can also contribute to the systemic 
inflammation.  
Here we show that Pg DNA can be found in the sub-gingival plaque and in saliva, 
rarely yet possibly in the PBMCs and even more rarely in plasma, but more frequently in the 
joint compartment (in the synovial tissue more than in the synovial fluid). Our data support 
the possibility that the genetic material was carried out from teeth to joints [28].  
The possibility that oral bacteria or their genetic material could reach the joints, was 
indeed proven by Moen et al. [15]. These Authors found more genetic material in the 
synovial fluid than in plasma, but they observed no relationship with the parameters of the 
inflammatory status (no correlation with CRP, white blood cells count, platelets). Therefore 
the possibility to have a migration from the oral to the joint compartment was hypothesized, 
though bacteria seemed to have no link with inflammation. Martinez-Martinez et al. [16] 
confirmed the possibility of a transport of oral genetic material to the joints, since they found 
among various oral pathogens also Pg more frequently in the synovial fluid than in serum and 
discussed the possibility of a free DNA transport to the joint compartment.  
Our data shed more light on the issue, since we observed that Pg DNA is present 
similarly in UPIA and RA, it is found in the whole blood (of interest more in UPIA than in 
RA), more rarely in plasma and in the synovial fluid, but it can be found in the synovial 
bioptic tissue in one third of RA patients. Although the sample size lacks the power for 
further assumptions, we also observed that the presence of Pg DNA associates with an 
increased PBMCs count in the peripheral blood, mostly with PMN cells, thus possibly 
contributing to the inflammatory status.  
We agree with previous papers that no strict relationship exists between the presence 
of Pg DNA and ACPA or RF levels [29]. Notably, the Pg DNA presence in the oral 
compartment was mostly observed in early RA patients than in long standing ones, in 
accordance with the recent findings by J.U. Scher et al. [29]. Furthermore, oral Pg DNA was 
associated with the DR4 epitope. This suggests that the persistence in ERA possibly relies in 
a defective clearance of Pg by RA patients DR4 carriers. This of course should be tested and 
verified in vitro and in further cohorts. The well defined immunostimulatory properties of Pg 
DNA, known to stimulate macrophages and fibroblasts to produce tumor necrosis factor 
alpha and interleukin-6 in a dose-dependent manner, might explain why its persistence could 
induce a more inflammatory intra-articular inflammation. These stimulatory effects are due to 
unmethylated CpG motifs within the bacterial DNA and may represent a continuous and 
persistent inflammatory loop [30]. 
 
Conclusions 
Albeit our data cannot support that the presence of Porphyromonas gingivalis DNA 
represents a surrogate marker for the occurrence of ACPA [31], certainly the presence of Pg 
DNA in UPIA and the presence in the synovial tissue of RA patients, suggests that the 
bacterium has a role in the pathogenesis of RA, which can still be maintained long after the 
initial disruption of the immunologic tolerance.  
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 Figure 1. White blood cells count and blood neutrophils count according to the 
positivity for Porphyromonas gingivalis in the sub-gingival plaque in RA patients. WBC: 
white blood cells; Neut.: neutrophils; PB: peripheral blood; Pg: Porphyromonas gingivalis. 
Table 1. Patients’ clinical and immunological characteristics. 
 RA UPIA Others pa pb pc 
Number 32 14 23 - - - 
Age, mean ± SD (years) 54.2 ± 17.9 47.8 ± 13.1 47.8 ± 16.7 ns ns ns 
N. females/males, (% F) 24/8 (75.0) 11/3 (78.6) 14/9 (60.9) ns ns ns 
Duration, mean ± SD (years) 6.5 ± 7.5 3.6 ± 5.3 3.8 ± 6.2 ns ns ns 
ESR, mean ± SD (mm 1sth) 62.1 ± 39.2 33.6 ± 26.8 35.9 ± 30.9 0.02 0.01 ns 
CRP, mean ± SD (mg/l) 40.7 ± 47.4 15.6 ± 16.9 28.6 ± 49.0 ns ns ns 
DAS, mean ± SD 3.74 ± 1.17 2.25 ± 0.85  <0.01 - - 
HAQ-DI, mean ± SD 1.40 ± 0.78 0.69 ± 0.91 0.91 ± 0.72 0.01 0.04 ns 
ACPA ≥ 5.0 U/ml (%) 13 (40.6) 1 (7.7) 1 (4.5) <0.01 <0.01 ns 
IgM RF ≥ 20.0 U/ml (%) 9 (28.1) 2 (15.4) 1 (4.5) ns 0.05 ns 
IgA RF ≥ 20.0 U/ml (%) 6 (18.8) 1 (7.7) 0 ns ns ns 
DMARDs therapy, n. (%) 27 (84.4) 8 (57.1) 19 (82.6) ns ns ns 
Biologic therapy, n. (%) 10 (31.3) 0 2 (8.7) 0.02 0.05 ns 
Steroid therapy, n. (%) 22 (68.8) 6 (42.9) 12 (52.2) ns ns ns 
RA = rheumatoid arthritis; UPIA = undifferentiated peripheral inflammatory arthritis; Others 
= other arthritides; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; DAS = 
disease activity score; HAQ-DI = health assessment questionnaire disability index; GH = 
global health; VAS = visual analogue scale; SD = standard deviation; ns = not significant. a= 
RA vs. UPIA, b = RA vs. Others, c = UPIA vs. Others. 
Table 2. Positive results for Porphyromonas gingivalis DNA. 
 RA UPIA Others 
Total 22/31 (71.0) 11/14 (78.6) 16/21 (76.2) 
Plasma 1/31 (3.2) 0/14 0/21 
Full peripheral blood 2/21 (9.5) 3/12 (25.0) 1/18 (5.6) 
Synovial fluid 2/30 (6.7) 1/12 (8.3) 1/20 (5.0) 
Synovial tissue 9/27 (33.3) 0/11 2/23 (8.7) 
Plaque 14/26 (53.8) 10/13 (76.9) 11/21 (52.4) 
All the values are considered as number of positives / total number (%). RA = rheumatoid 
arthritis; UPIA = undifferentiated peripheral inflammatory arthritis; Others = other 
arthritides.  
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Additional file 1. Table S1. Patients list with demographic, genetic and immunologic data 
and positivity for Porphyromonas gingivalis. 
Additional file 2. Figure S1. Positivity for Porphyromonas gingivalis DNA in the synovial 
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tissue, ACPA positivity, smoking status and HLA DRB1*04 allele. 
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